Fundacio Ace Institut Catala De Neurociencies Aplicades — Clinical Trial Site

32 Registered trials

8 Currently recruiting

Organisation

Fundacio Ace Institut Catala De Neurociencies Aplicades

Location

Barcelona, Spain

Identifier

ORG-100042189

Address

Gran Via De Carles III 85 Bis, 08028, Spain

Departments

#40612:Neurology Department
Alzheimer Treatment & Research Center
Institut Catala de Neurocienies Aplicades
N/A
Neurología
Neurology
Unidad de valoración de la memoria y demencias

Clinical trials at this site (32)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Not authorised

2024-514411-95-00 Amnestic mild cognitive impairment (aMCI, single or mul 4
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheime… Recruiting

2023-509807-34-00 Early Alzheimer’s Disease (Mild Cognitive Impairment an 4 2024-08-12
Brain imaging to understand early changes in dementia related diseases Recruiting

2025-523284-37-00 Dementia 4 2026-06-11
First-in-Human Study of RO7812653 Recruiting

2025-522101-37-00 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cogn 1 2026-02-17
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
A clinical study of MK-2214 in people with Alzheimer’s disease (MK-2214-004) Recruiting

2024-519190-19-00 Alzheimer’s Disease 4 2025-10-03
A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, … Recruiting

2022-500069-29-00 Alzheimer's disease 9 2022-11-02
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Alzheimer Disease Dementia Brain Diseases Central 5 2025-12-04
A Study of Remternetug in Early Alzheimer’s Disease Ended

2024-515656-20-00 Alzheimer’s Disease 5 2025-04-15
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Alzheimer's disease 9 2024-06-27
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
AHEAD 3-45 Study: A Clinical Study to Investigate the Effects of BAN2401 in Subjects With Preclinical Alzheimer’s Disease Ended

2024-510888-39-00 Preclinical Alzheimer’s Disease and Elevated Amyloid 5 2021-07-21
A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended

2024-510887-22-00 Mild cognitive impairment due to Alzheimer's disease or 5 2019-09-30
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404… Halted

2023-505096-68-00 Preclinical Alzheimer’s Disease 4 2025-01-14
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th… Ended

2024-515539-31-00 Alzheimer’s disease dementia 4 2025-04-01
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 4 2024-05-07
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102 Ended

2023-503729-20-00 Alzheimer’s Disease 3 2024-03-27
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Ended

2022-503148-41-00 Alzheimer's disease 4 2023-12-01